- $1.56bn
- $1.29bn
- $16.10m
Newscasts - Experimental gene therapy slows Huntington's disease in trial
UniQure triples after brain disorder therapy slows disease progression in trial
UniQure doubles after brain disorder therapy slows disease progression in trial
UniQure's brain disorder drug slows disease progression in trial (updated)
Brief: uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
uniQure's brain disorder drug meets trial goal
Brief: Uniqure NV May Offer Ordinary Shares Offering Price Of Up To $200 Million From Time To Time Through Leerink Partners- SEC Filing
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs
Brief: UniQure Provides Regulatory Update On Amt-130 For Huntington’S Disease
Brief: Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease
UniQure slides on pricing $75 mln stock offering
Brief: UniQure Announces Pricing Of Its Public Offering
Brief: Uniqure Announces Proposed Public Offering
Brief: Uniqure NV Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
UniQure slides on stock offering plans
U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen
UniQure doubles on alignment with FDA on development plan for gene therapy
UniQure jumps on alignment with FDA on development plan for gene therapy
Brief: Uniqure Announces Alignment With FDA On Accelerated Approval Pathway For AMT-130 In Huntington’S Disease